CTMC vs RoslinCT: CDMO Comparison

Side-by-side comparison of CTMC and RoslinCT on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

CTMC → 63.0
Houston, TX
Signal Score
63/100
Quality (FDA + GMP)
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
Modalities
CAR-T, Cell Therapy, Gene Editing
Edinburgh, UK · Hopkinton, MA
Signal Score
80/100
Quality (FDA + GMP)
99/100
FDA inspections
1
— NAI / VAI / OAI
0 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
Available
Modalities
CAR-T, Cell Therapy, iPSC, Gene Editing

Key differences

  • RoslinCT has FDA inspections on record (1); CTMC does not yet appear in the FDA inspection database.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • RoslinCT maintains 1 MHRA / UK GMP certificate; CTMC does not.
  • Composite Signal Score: RoslinCT 80/100 vs CTMC 63/100 — a 17-point gap reflecting the combined quality, capacity and financial signal.

On a 13-modality CDMO landscape, both CTMC and RoslinCT qualify as CAR-T manufacturers; RoslinCT carries the higher composite Signal Score for CAR-T programs in this comparison.

What to evaluate for CAR-T programs

Both CTMC and RoslinCT qualify as CAR-T CDMOs. When choosing between them for CAR-T programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

Vector supply

CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.

Autologous logistics & turnaround

Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.

Closed, scalable processing

Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

See all CAR-T CDMOs ranked by Signal Score →

Frequently asked: CTMC vs RoslinCT

Which has the stronger FDA inspection record, CTMC or RoslinCT?

Both CTMC and RoslinCT maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. CTMC has 0 FDA inspections on record; RoslinCT has 1.

How do CTMC and RoslinCT compare on European GMP coverage?

CTMC holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. RoslinCT holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is better for CAR-T manufacturing — CTMC or RoslinCT?

Both CTMC and RoslinCT are tagged as CAR-T CDMOs in our directory, so both are credible options for CAR-T programs. The most important differentiator for CAR-T selection is typically vector supply: CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

CTMC carries a Signal Score of 63/100 and RoslinCT carries 80/100 — a meaningful lead for RoslinCT. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating CTMC and RoslinCT for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.